August 14, 2020

The Niche

Knoepfler lab stem cell blog

NeoStem

2 min read

To get from point A of a stem cell discovery to point B of a patient actually receiving a treatment based on that discovery is a long and non-linear road, which requires biotech company research. Stem cell biotech companies including publicly traded companies are an integral part of the field making that journey. How those companies fare financially is not just of interest to investors, but also should be on the radar screen of scientists and advocates too. Lately, stem cell companies have not …Read More

4 min read

Each year towards the end of December I make predictions for the coming year as I did for 2015. In the past I usually make a top 10 prediction list, but for this year I made 20 predictions. Admittedly some of them may have been more hopes than predictions. At mid-year today on June 30th, how am I doing with 2015 predictions? See below. Note that of course for some the jury is still out. BTW, stay tuned for more on an upcoming update …Read More

1 min read

CIRM has reinvented itself in a new form, CIRM 2.0, under the leadership of its new President Randy Mills. CIRM is almost like a stem cell that has changed into another new kind of stem cell. Us scientists could see the change coming in the “programming” at CIRM in terms of how it was operating as the 2.0 version, but what would it bring in practical terms? We are starting to see the new CIRM 2.0 in action and by all signs it looks pretty …Read More